U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C8H7O3.Na
Molecular Weight 174.1291
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SODIUM MANDELATE

SMILES

[Na+].OC(C([O-])=O)C1=CC=CC=C1

InChI

InChIKey=FWDLHTBMGQEUDU-UHFFFAOYSA-M
InChI=1S/C8H8O3.Na/c9-7(8(10)11)6-4-2-1-3-5-6;/h1-5,7,9H,(H,10,11);/q;+1/p-1

HIDE SMILES / InChI

Molecular Formula Na
Molecular Weight 22.98976928
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C8H7O3
Molecular Weight 151.1394
Charge -1
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: description was created based on several sources, including, http://dermage.com.br/dermage/paginas/article.pdf

Mandelic acid is an aromatic alpha hydroxy acid that is used for the treatment of urinary tract infections. The drug is marketed in Canada under the name Mandelamine (as a complex with methenamine). Mandelic acid exerts its antibacterial effect mainly by increasing urine acidity. Moreover, mandelic acid is used as a serum for the treatment of wrinkles.

Approval Year

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Mandelamine

Approved Use

For the suppression or elimination of bacteriuria associated with pyelonephritis, cystitis and other urinary tract infections.
Doses

Doses

DosePopulationAdverse events​
45 % 1 times / 2 weeks multiple, topical
Dose: 45 %, 1 times / 2 weeks
Route: topical
Route: multiple
Dose: 45 %, 1 times / 2 weeks
Sources:
unhealthy, 19.4
Health Status: unhealthy
Age Group: 19.4
Sex: M+F
Sources:
Other AEs: Burning sensation, Erythema...
Other AEs:
Burning sensation (1 patient)
Erythema (2 patients)
Sources:
1 % 2 times / day multiple, topical
Dose: 1 %, 2 times / day
Route: topical
Route: multiple
Dose: 1 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sex: M+F
Sources:
Other AEs: Skin erythema desquamative...
Other AEs:
Skin erythema desquamative (5%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Burning sensation 1 patient
45 % 1 times / 2 weeks multiple, topical
Dose: 45 %, 1 times / 2 weeks
Route: topical
Route: multiple
Dose: 45 %, 1 times / 2 weeks
Sources:
unhealthy, 19.4
Health Status: unhealthy
Age Group: 19.4
Sex: M+F
Sources:
Erythema 2 patients
45 % 1 times / 2 weeks multiple, topical
Dose: 45 %, 1 times / 2 weeks
Route: topical
Route: multiple
Dose: 45 %, 1 times / 2 weeks
Sources:
unhealthy, 19.4
Health Status: unhealthy
Age Group: 19.4
Sex: M+F
Sources:
Skin erythema desquamative 5%
1 % 2 times / day multiple, topical
Dose: 1 %, 2 times / day
Route: topical
Route: multiple
Dose: 1 %, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Sex: M+F
Sources:
PubMed

PubMed

TitleDatePubMed
Current trends in quantitative structure activity relationships on FXa inhibitors: evaluation and comparative analysis.
2004-11
Prevalence of varicose veins and venous anatomy in patients without truncal saphenous reflux.
2004-10
Role of glycine 81 in (S)-mandelate dehydrogenase from Pseudomonas putida in substrate specificity and oxidase activity.
2004-08-24
Heptakis(6-amino-6-deoxy)-beta-cyclodextrin as a chiral selector for the separation of anionic analyte enantiomers by capillary electrophoresis.
2004-08
Influence of (hydroxy)alkylamino substituents on enantioseparation ability of single-isomer amino-beta-cyclodextrin derivatives in chiral capillary electrophoresis.
2004-08
Determination of urinary styrene metabolites in the general Italian population by liquid chromatography-tandem mass spectrometry.
2004-08
Altered substrate specificity in flavocytochrome b2: structural insights into the mechanism of L-lactate dehydrogenation.
2004-07-27
Mandelamide hydrolase from Pseudomonas putida: characterization of a new member of the amidase signature family.
2004-06-22
Cytogenetic markers, DNA single-strand breaks, urinary metabolites, and DNA repair rates in styrene-exposed lamination workers.
2004-06
Exceptional chiral recognition of racemic carboxylic acids by calix[4]arenes bearing optically pure alpha,beta-amino alcohol groups.
2004-04-15
Hydrophobic nature of the active site of mandelate racemase.
2004-03-09
Evaluation of the efficiency of respiratory protective equipment based on the biological monitoring of styrene in fibreglass reinforced plastics industries.
2004-03
Chiral synthesis of (2S,3S)-2-(2-morpholin-2-yl-2-phenylmethoxy)phenol.
2004-03
Human urine certified reference material CZ 6009: creatinine, styrene metabolites (mandelic acid and phenylglyoxylic acid).
2004-03
Esters of mandelic acid as substrates for (S)-mandelate dehydrogenase from Pseudomonas putida: implications for the reaction mechanism.
2004-02-24
Synthesis and antibiotic activity of the tricyclic furo[3,2-c] isochromen-2-trione unit of the pyranonaphthoquinones.
2004-02-09
Quininium (R)-mandelate, a structure with large Z' described as an incommensurately modulated structure in (3+1)-dimensional superspace.
2004-02
High resolution structures of an oxidized and reduced flavoprotein. The water switch in a soluble form of (S)-mandelate dehydrogenase.
2004-01-30
Construction of an electro-enzymatic bioreactor for the production of (R)-mandelate from benzoylformate.
2004-01
A rapid HPLC method for the determination of carboxylic acids in human urine using a monolithic column.
2004-01
Synthesis of optically active atropisomeric anilide derivatives through diastereoselective N-allylation with a chiral Pd-pi-allyl catalyst.
2003-12-12
A transient intermediate in the reaction catalyzed by (S)-mandelate dehydrogenase from Pseudomonas putida.
2003-11-11
C4'-spiroalkylated nucleosides having sulfur incorporated at the apex position.
2003-10-31
A high-throughput amenable colorimetric assay for enantioselective screening of nitrilase-producing microorganisms using pH sensitive indicators.
2003-10
Nitration of endogenous para-hydroxyphenylacetic acid and the metabolism of nitrotyrosine.
2003-09-01
[Experimental study on the in vitro resistance to Toxoplasma gondii by murine lymphocyte].
2003-09
Exposure assessment of monoterpenes and styrene: a comparison of air sampling and biomonitoring.
2003-08
Inhibition of mandelate racemase by alpha-fluorobenzylphosphonates.
2003-06-16
Sperm-FISH analysis and human monitoring: a study on workers occupationally exposed to styrene.
2003-06-06
Comparison of isotopic fractionation in lactic acid and ethanol fermentations.
2003-06
Asymmetric environments in encapsulation complexes.
2003-05-21
Use of ionic liquids in a lipase-facilitated supported liquid membrane.
2003-05
Effects of clay minerals on Cr(VI) reduction by organic compounds.
2003-05
Use of short-end injection capillary packed with a glycopeptide antibiotic stationary phase in electrochromatography and capillary liquid chromatography for the enantiomeric separation of hydroxy acids.
2003-03-21
Solvent ototoxicity in the rat and guinea pig.
2003-03-14
A glycopeptide antibiotic chiral stationary phase for the enantiomer resolution of hydroxy acid derivatives by capillary electrochromatography.
2003-03
Structural and kinetic analysis of catalysis by a thiamin diphosphate-dependent enzyme, benzoylformate decarboxylase.
2003-02-25
The mandelamide keto-enol system in aqueous solution. Generation of the enol by hydration of phenylcarbamoylcarbene.
2003-01-08
Nonlinear amplification of circular dichroism activity upon cyclodimerization of a chiral saddle-shaped porphyrin.
2003-01-07
Chloride present in biological samples as a tool for enhancement of sensitivity in capillary zone electrophoretic analysis of anionic trace analytes.
2003-01
The role of various biomarkers in the evaluation of styrene genotoxicity.
2003
Relation between colour vision loss and occupational styrene exposure level.
2002-12
Interest of genotyping and phenotyping of drug-metabolizing enzymes for the interpretation of biological monitoring of exposure to styrene.
2002-12
Fluorescent sensors for the enantioselective recognition of mandelic acid: signal amplification by dendritic branching.
2002-11-27
Use of mandelic acid condensation polymer (SAMMA), a new antimicrobial contraceptive agent, for vaginal prophylaxis.
2002-11
Assessment of sperm DNA integrity in workers exposed to styrene.
2002-11
[A study on the adduct characteristics of styrene and DNA].
2002-10
High-throughput screening of enantioselective catalysts by immunoassay.
2002-01-04
Liquid chromatography/electrospray tandem mass spectrometry characterization of styrene metabolism in man and in rat.
2002
[Efficacy of mandelic acid in treating acute toxoplasmosis in mice].
2001
Patents

Sample Use Guides

500 mg - 2 tablets 4 times a day (in the form of (Methenamine Mandelate Tablets U.S.P.).
Route of Administration: Oral
In Vitro Use Guide
Antimicrobal activity of mandelic acid was determined by disc diffusion method. S. aureus type strains (ATCC 700698 and ATCC 25923) and 19 isolates were incubated with 10 ul of 160, 80, 40, 30, 20 and 10 mg/ml of the acid. Concentrations required to inhibit 50 and 90% of the clinical isolates (MIC50 and MIC90) were 20 and 40 (mg/ml) respectively and those required to kill 50 and 90% of the strains (MBC50 and MBC90) were 20 and 80 (mg/ml) respectively.
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:48:37 GMT 2025
Edited
by admin
on Mon Mar 31 17:48:37 GMT 2025
Record UNII
83WBN2F871
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MANDELIC ACID SODIUM SALT
MI  
Preferred Name English
SODIUM MANDELATE
Common Name English
DL-SODIUM MANDELATE
Common Name English
MANDELIC ACID SODIUM SALT [MI]
Common Name English
MANDELIC ACID, SODIUM SALT
Common Name English
SODIUM PHENYLGLYCOLATE
Systematic Name English
Code System Code Type Description
MERCK INDEX
m7051
Created by admin on Mon Mar 31 17:48:37 GMT 2025 , Edited by admin on Mon Mar 31 17:48:37 GMT 2025
PRIMARY Merck Index
FDA UNII
83WBN2F871
Created by admin on Mon Mar 31 17:48:37 GMT 2025 , Edited by admin on Mon Mar 31 17:48:37 GMT 2025
PRIMARY
CAS
114-21-6
Created by admin on Mon Mar 31 17:48:37 GMT 2025 , Edited by admin on Mon Mar 31 17:48:37 GMT 2025
PRIMARY
PUBCHEM
23675514
Created by admin on Mon Mar 31 17:48:37 GMT 2025 , Edited by admin on Mon Mar 31 17:48:37 GMT 2025
PRIMARY
ECHA (EC/EINECS)
204-041-7
Created by admin on Mon Mar 31 17:48:37 GMT 2025 , Edited by admin on Mon Mar 31 17:48:37 GMT 2025
PRIMARY
EPA CompTox
DTXSID30921254
Created by admin on Mon Mar 31 17:48:37 GMT 2025 , Edited by admin on Mon Mar 31 17:48:37 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE